Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: Systematic review with meta-analysis

Journal of Thoracic Oncology

Volumn 5, Issue 12, 2010, Pages 1986-1993

  Lima, João Paulo S N ^a   Dos Santos, Lucas Vieira ^a   Sasse, Emma Chen ^b   Lima, Carmen Silvia Passos ^b   Sasse, André Deeke ^b,c  

^a BARRETOS CANCER HOSPITAL   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c Radium Instituto de Oncologia   (Brazil)

Author keywords

Antineoplastic agents; Drug therapy; Lung neoplasms; Meta analysis; Small cell lung carcinoma

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN; PLATINUM DERIVATIVE; TOPOTECAN;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DIARRHEA; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FEBRILE NEUTROPENIA; HAZARD RATIO; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 78650513543     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f2451c     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/ cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-2535.
3. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. (Pubitemid 46630948)
4. Lorigan P, Woll PJ, OBrien ME, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005;97:666-674. (Pubitemid 40812630)
5. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801. (Pubitemid 29269249)
6. Jones D, Klementich VFL, R., et al. Phase II trial of Docetaxel and Carboplatin in patients with newly diagnosed, extensive-stage, small cell carcinoma of the lung (SCLC). J Clin Oncol 2005;23:Abstract 7346.
7. Gridelli C, Perrone F, Ianniello GP, et al. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensivestage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol 1998;16:1414-1419. (Pubitemid 28175759)
8. Dimitroulis J, Rapti A, Stathopoulos GP, et al. Comparison of cisplatinpaclitaxel combination versus cisplatin-etoposide in patients with smallcell lung cancer: a phase III study. Oncol Rep 2008;20:879-884.
9. Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin- etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001;12:463-470. (Pubitemid 32472099)
10. Niell HB, Herndon JE 2nd, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005;23:3752-3759. (Pubitemid 46252471)
11. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): interim results. 2008 ASCO meeting, Category Lung Cancer Local-Regional and Adjuvant Therapy, Abs NSA.
12. Negoro S, Fukuoka M, Niitani H, et al. [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group]. Gan To Kagaku Ryoho 1991;18:1013-1019.
13. Rocha-Lima CM, Herndon JE 2nd, Lee ME, et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol 2007;18:331-337.
14. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-1229.
15. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91. (Pubitemid 34438898)
16. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043. (Pubitemid 46622112)
17. Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008;26:4261-4267.
18. Sørensen M, Felip E, ESMO Guidelines Working Group. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008:ii41-ii42.
19. Kalemkerian GP, Akerley W, Downey RJ, et al. Small cell lung cancer. J Natl Compr Canc Netw 2008;6:294-314. (Pubitemid 351488824)
20. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006;24:2044-2051. (Pubitemid 46622113)
21. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896-1900.
22. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834. (Pubitemid 28562978)
23. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. (Pubitemid 47161711)
24. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. In M Egger, GD Smith, DG Altman (Eds.), Systematic Reviews in Health Care: Metaanalysis in Context, 2nd Ed. London: BMJ Publication Group, 2001, pp 189-210.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control ClinTrials 1986;7:177-188. (Pubitemid 17189972)
26. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
27. Seiter K. Toxicity of the topoisomerase I inhibitors. Expert Opin Drug Saf 2005;4:45-53.
28. Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II-mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 2006;29:209-230.
29. Pan D, Hou M, Li H, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: a randomized clinical trial. Chin J Lung Cancer 2006;9:443-446. (Pubitemid 44646018)
30. Heigener DF, Freitag L, Eschbach C, et al. Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive diseasesmall cell lung cancer (ED-SCLC): final results of a randomised phase III trial. J Clin Oncol 2008;26:Abstract 7513.
31. Zhang S, Wang J, Wang Q, et al. A randomized study comparing topotecan plus cisplatin versus etoposide plus carboplatin for previously untreated small cell lung cancer. Chin J Lung Cancer 2007;10:144-147. (Pubitemid 46658492)
32. Schmittel AH, Sebastian M, Fischer von Weikersthal L, et al. Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: results of the German randomized phase III trial. J Clin Oncol 2009;27:Abstract 8029.
33. Natale RB, Lara PN, Chansky K, et al. S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). J Clin Oncol 2008;26:Abstract 7512.
34. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-2092. (Pubitemid 46972795)
35. Ardizzoni A, Manegold C, Debruyne C, et al. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003; 9:143-150. (Pubitemid 36109726)
36. Naka N, Kawahara M, Okishio K, et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 2002;37:319-323. (Pubitemid 35286732)
37. Hirose T, Horichi N, Ohmori T, et al. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer 2003;40:333-338. (Pubitemid 36627714)
38. Takigawa N, Fujiwara K, Ueoka H, et al. Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study. Anticancer Res 2003;23:557-560. (Pubitemid 36358450)
39. Ioannidis JP. Interpretation of tests of heterogeneity and bias in metaanalysis. J Eval Clin Pract 2008;14:951-957.
40. Hande K, Messenger M, Wagner J, et al. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 1999;5:2742-2747. (Pubitemid 29493947)
41. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993;11:374-377.
42. Hotta K, Kiura K, Fujiwara Y, et al. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Ann Oncol 2009;20:829-834.
43. Yao N, Jiang L, Yang K, et al. [Irinotecan/cisplatin versus Etoposide/ cisplatin for patients with extensive stage small cell lung cancer: a systematic review]. Chin J Lung Cancer 2009;12:884-888.